- Home
- DJT vs CLDX Comparison
DJT vs CLDX Comparison
Compare DJT & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJT | CLDX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | 31 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | DJT | CLDX |
|---|---|---|
| Price | $7.90 | $30.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | ★ 3.6M | 631.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | N/A | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $7.86 | $18.56 |
| 52 Week High | $27.00 | $35.83 |
Technical Indicators
Market Signals| Indicator | DJT | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 42.39 |
| Support Level | N/A | $28.30 |
| Resistance Level | $10.55 | $30.90 |
| Average True Range (ATR) | 0.35 | 1.45 |
| MACD | -0.10 | -0.33 |
| Stochastic Oscillator | 2.92 | 26.46 |
Price Performance
Historical ComparisonAbout DJT Trump Media & Technology Group Corp.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.